Catalyst
Slingshot members are tracking this event:
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia Phase 3 Study Completed
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NKTR | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 07, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Inhaled Amikacin Solution, Bay41-6551, Gram-negative Pneumonia
